SynCore Biotechnology Co.,Ltd (4192.TWO)
- Previous Close
29.60 - Open
28.95 - Bid 29.60 x --
- Ask 30.25 x --
- Day's Range
28.95 - 29.60 - 52 Week Range
24.70 - 48.35 - Volume
28 - Avg. Volume
7,055 - Market Cap (intraday)
1.041B - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
-- - EPS (TTM)
-1.55 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts EGW; and SB04, a conventional drug for the treatment of age-related macular degeneration dry AMD that is in Phase II/III clinical trials. In addition, the company provides SB05-EndoTAG-1, a conventional drug for pancreatic cancer and triple-negative breast cancer that is in Phase III clinical trials. Further, it distributes cameras under the epiCam name that is used in recording the progress of ophthalmology diseases. The company has partnerships with Medigene AG, MacuCLEAR Inc.; and Sinphar Pharmaceutical Co., Ltd.; and The National Health Research Institutes NHRI. SynCore Biotechnology Co.,Ltd was incorporated in 2008 and is headquartered in Yilan City, Taiwan. The company is a subsidiary of Sinphar Pharmaceutical Co., Ltd.
www.syncorebio.comRecent News: 4192.TWO
View MorePerformance Overview: 4192.TWO
Trailing total returns as of 5/27/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4192.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4192.TWO
View MoreValuation Measures
Market Cap
1.04B
Enterprise Value
852.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
42.76
Price/Book (mrq)
3.72
Enterprise Value/Revenue
35.04
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-232.61%
Return on Assets (ttm)
-10.37%
Return on Equity (ttm)
-16.66%
Revenue (ttm)
23.34M
Net Income Avi to Common (ttm)
-54.28M
Diluted EPS (ttm)
-1.55
Balance Sheet and Cash Flow
Total Cash (mrq)
212.44M
Total Debt/Equity (mrq)
2.64%
Levered Free Cash Flow (ttm)
-31.41M